BMO Capital lowered the firm’s price target on 4D Molecular (FDMT) to $40 from $63 and keeps an Outperform rating on the shares. The firm says that while the Phase II extension cohort data for 4D-150 in wet age-related macular degeneration appear to beat investor expectations, for the first time management treated patients with a second supplemental injection at four weeks, positively biasing the results and preventing comparison with 4D Molecular dose expansion data and Regenxbio (RGNX)/Adverum Biotechnologies (ADVM) data. Given the healthier baseline of extension cohort versus dose expansion cohort, BMO finds the second supplementary injection surprising and look for additional color on intentions, the analyst tells investors in a research note. Shares of 4D are down 25%, or $6.56, to $20.19 in morning trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
- FDA clears 4D Molecular’s IND Application for 4D-175 for GA treatment
- 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
- 4D Molecular presents interim data from Phase 1/2 AEROW trial
- 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference